According to the manufacturer of Bapten, a drug used for the treatment of tendinitis of the superficial digital flexor tendon in the horse, the drug is again on the market. There was a “stop-sale” on Bapten in Oct. 1998 due to “a small number of reports of apparent excessive swelling post treatment,” according to Boehringer Ingelheim.

To continue reading this article, become a member of TheHorse.com.

It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.

Sign In